Effect of Coronary Percutaneous Revascularization on Interferon-γ and Interleukin-10 Producing CD4+ T Cells during Acute Myocardial Infarction

T lymphocytes play an important role in the induction and progression of acute coronary syndromes (ACS). To gain insight into how different T cell subsets can influence ACS, we analyzed the frequencies of circulating CD4+T cells producing either pro-inflammatory interferon(IFN)-γ or anti-inflammatory interleukin (IL)-10 in subjects presenting with ST-elevation myocardial infarction (STEMI). The effect of coronary bare metal (BS) and paclitaxel-eluting stent (PES) on the balance between CD4+IFN-γ+ and CD4+IL-10+ lymphocytes was also investigated. Peripheral blood mononuclear cells (PBMC) were isolated from 38 consecutive patients with STEMI before and 48 hrs or 6 days after implantation of either BS or PES. Twenty patients with no history of coronary artery disease were included as basal controls. PBMC were stimulated in vitro with anti-CD3/anti-CD28 monoclonal antibodies, and CD4+IFN-γ+ or CD4+IL-10+ T cells were detected by flow cytometry intracellular staining. The frequency of peripheral CD4+IL-10+ T cells was significantly higher in STEMI patients as compared with controls. Conversely, the frequency of CD4+IFN-γ+ T lymphocytes did not differ between STEMI and subjects without history of coronary artery disease. Six days after the revascularization procedure, the percentage of CD4+IL-10+ T cells was significantly decreased in BS but not in the PES group, whereas the relative percentage of CD4+IFN-γ+ T lymphocytes were diminished in both groups as compared with baseline levels. Our data indicate that STEMI is associated with a peripheral expansion of CD4+IL-10+T lymphocytes, and that primary coronary revascularization with implantation of either BS or PES is followed by a reduction in circulating CD4+IFN-γ+ T lymphocytes. PES implantation, however, appears to inhibit the relative decrease of the IL-10 producing lymphocyte as observed in BS implanted patients, shifting the balance between pro-inflammatory and anti-inflammatory T cell populations in favor of the latter.

[1]  T. Lagerweij,et al.  The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. , 2007, Atherosclerosis.

[2]  F. Fedele,et al.  Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. , 2007, Thrombosis research.

[3]  G. Keren,et al.  Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. , 2006, European heart journal.

[4]  J. Tijssen,et al.  Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. , 2006, The New England journal of medicine.

[5]  B. Nakken,et al.  Th1/Th2 Imbalance, Measured by Circulating and Intracytoplasmic Inflammatory Cytokines – Immunological Alterations in Acute Coronary Syndrome and Stable Coronary Artery Disease , 2006, Scandinavian journal of immunology.

[6]  K. Hatakeyama,et al.  Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy. , 2006, European heart journal.

[7]  A. Kirtane,et al.  Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. , 2006, The American journal of cardiology.

[8]  T. Kılıç,et al.  Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome , 2006, Heart.

[9]  R. Flavell,et al.  Natural regulatory T cells control the development of atherosclerosis in mice , 2006, Nature Medicine.

[10]  G. Keren,et al.  Altered status of CD 4 1 CD 25 1 regulatory T cells in patients with acute coronary syndromes , 2006 .

[11]  Ildikó Kriszbacher,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.

[12]  E. Edelman,et al.  Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. , 2005, Journal of the American College of Cardiology.

[13]  F. Alfonso,et al.  Fatal infection after rapamycin eluting coronary stent implantation , 2005, Heart.

[14]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[15]  F. Fedele,et al.  Integrin β2-Chain (CD18) Over-Expression on CD4+ T Cells and Monocytes after Ischemia/Reperfusion in Patients Undergoing Primary Percutaneous Revascularization , 2004, International journal of immunopathology and pharmacology.

[16]  E. Bruera,et al.  Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. , 2004, Cytokine.

[17]  M. Battaglia,et al.  The role of interleukin 10 in the control of autoimmunity. , 2003, Journal of autoimmunity.

[18]  M. D’Elios,et al.  T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Heeschen,et al.  Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.

[20]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[21]  G. Hansson,et al.  Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. , 2002, The Journal of clinical investigation.

[22]  J. Kaski,et al.  Serum Levels of the Antiinflammatory Cytokine Interleukin-10 Are Decreased in Patients With Unstable Angina , 2001, Circulation.

[23]  R. de Waal Malefyt,et al.  IFN-α and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells1 , 2001, The Journal of Immunology.

[24]  M. Zembala,et al.  Three-Color Flow Cytometry Detection of Intracellular Cytokines in Peripheral Blood Mononuclear Cells: Comparative Analysis of Phorbol Myristate Acetate-Ionomycin and Phytohemagglutinin Stimulation , 2001, Clinical Diagnostic Laboratory Immunology.

[25]  A. Maseri,et al.  Evidence for Antigen-Driven T-Cell Response in Unstable Angina , 2000, Circulation.

[26]  R. Frye,et al.  Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. , 2000, Circulation.

[27]  M. Territo,et al.  Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  M. Bureau,et al.  Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.

[29]  A Daugherty,et al.  The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. , 1997, The Journal of clinical investigation.

[30]  J. D. de Vries,et al.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells , 1996, The Journal of experimental medicine.

[31]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[32]  G. Hansson,et al.  Immune mechanisms in atherosclerosis. , 1989, Arteriosclerosis.